News & Updates

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Artificial intelligence (AI) can help diagnose thyroid eye disease (TED) and assess for severity by analysing CT scans, reports an expert at ARVO 2023.

In the treatment of moderate-to-severe meibomian gland dysfunction (MGD), a 3-week course of oral azithromycin leads to outcomes that are similar to that achieved with a 6-week course of oral doxycycline, according to a study.

Ocular hypertension (OHT) and macular edema (ME) are the most common and relevant adverse events (AEs) following neodymium:yttrium-aluminum-garnet posterior capsulotomy (Nd:YAG-caps), reports a study. These AEs normally occur within 3 months after the procedure, which stresses the need for a close follow-up during this period or a delayed capsulotomy.

New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Switching from other anti-VEGF* agents to brolucizumab only helps improve visual acuity and reduces disease activity in patients with neovascular (wet) age-related macular degeneration (nAMD)

Diabetic macular oedema (DME) patients with visual acuity (VA) of 20/50 or worse are likely to experience superior clinically relevant VA outcomes at 1 year and over 2 years using aflibercept vs bevacizumab or ranibizumab, according to an analysis of Diabetic Retinopathy Clinical Research (DRCR) Network’s Protocol T data presented at the 38^th Asia-Pacific Academy of Ophthalmology (APAO 2023) Congress.

The use of repeated low-level red-light intervention helps prevent myopia in children with premyopia, as reported in a study.